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1. Introduction 
Autoimmune diseases of the liver and biliary tract are inflammatory diseases of unknown 
origin that progress spontaneously, in most cases, to severe fibrosis and cirrhosis (Maggiore 
et al, 2009). They are characterized by an inflammatory infiltrate in the liver tissue involving 
the lobule and the portal tract and, most frequently, by the presence of non-organ and liver-
specific autoantibody reactivity (Mieli Vergani  & Vergani, 2009). There are at least three 
principal disorders in humans, in which the liver damage is thought to be caused by an 
autoimmune mechanism: autoimmune hepatitis (AIH), where the target of the autoimmune 
attack is the hepatocyte, and two other conditions, autoimmune cholangitis (AIC) and 
primary biliary cirrhosis (PBC), where the target is the cholangiocyte. Between these three 
disorders exists a range of overlap of liver damage both at diagnosis and/or during the 
follow-up, recognized as “overlap syndrome” (Alvarez, 2006). Any autoimmune disorder 
may overlap with the other two. Autoimmune cholangitis may be limited, at diagnosis and 
during the follow-up, to the smallest intrahepatic (forth order) bile ducts in case of the so-
called “small duct sclerosing cholangitis” (Chapman, 2002), or may be diffuse affecting also 
larger bile duct and giving the typical radiological or MRI imaging of “sclerosing 
cholangitis”).  In children, primary biliary cirrhosis is exceptionally described, particularly 
before adolescence. Moreover, a rare and peculiar form of autoimmune hepatitis, typical of 
infancy exists, and is characterized by the unique association of Coombs positive 
autoimmune hemolytic anemia with the peculiar histopathological finding of diffuse giant 
cell transformation of the hepatocytes at a very unusual age even for infants (Maggiore et al, 
2011).  
Immunosuppressive treatment is usually efficacious in most cases of AIH, but it is less 
effective in autoimmune cholangitis, particularly in case of delayed diagnosis at the stage of 
diffuse sclerosing cholangitis (Maggiore et al, 2009). Immunosuppressive treatment is also 
the only life-saving treatment recognized in “infantile giant cell hepatitis associated with 
autoimmune hemolytic anemia” (Maggiore et al, 2011). 
Liver biopsy is of paramount importance in the diagnostic work-up of autoimmune diseases 
of the liver and biliary tract as recognized by the major guidelines. Histological examination 
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of liver tissue allow to confirm the diagnosis through the presence of suggestive features; to 
evaluate the degree of biliary tract damage; to establish the severity of architectural  injury  
and the eventual presence of cirrhosis and when necessary, to confirm the diagnosis of 
relapse in case of discontinuation of treatment. 
2. Autoimmune hepatitis 
Autoimmune hepatitis is a severe liver disease carrying a high mortality rate if untreated. 
All ages and genders are affected, with a peak of incidence in prepubertal girls, even if the 
disease has been diagnosed as early as age six months. The disease often presents acutely or 
can follow a chronic but fluctuating course, usually progressing to cirrhosis and liver failure, 
even though the rapidity of progression to end-stage liver diseases is highly variable (Lohse 
AW & Mieli-Vergani, 2011). 
Waldenström first described this disease entity in 1950 in a young woman with a chronic 
inflammatory liver disease, rapidly evolving to cirrhosis, elevated gamma globulins and 
amenorrhea. The disease was defined as “lupoid hepatitis” because of the presence of 
antinuclear antibodies (ANA) and of lupus erythematosus cells. Further progress in the 
identification and characterization of the autoantibodies typically present in AIH patients, 
led to a consensus on the definition and classification of this disease.  
Autoimmune hepatitis is a rare disease, occurring in all races and in all geographic areas, 
but with a wide range of prevalence in different populations. Studies in adults have 
reported, in Europe, a prevalence of 1: 10.000 (Boberg, 2002); however the insidious 
character of the disease in some patients suggests a considerable higher frequency. In 
childhood, the incidence of AIH is unknown, but it is apparently increasing in the last 20 
years, representing today about 10% of all chronic liver diseases in patients referred to a 
tertiary pediatric liver centre, in Europe (Mieli Vergani & Vergani, 2008). Female gender is 
mostly involved, with an F/M ratio from 3:1 up to 9:1. Even though all ages are affected, 
AIH is mainly a pediatric disease since about 40% of diagnoses of AIH-1 and 80% of AIH-2 
are made during childhood and adolescence (Alvarez, 2009). 
2.2 Pathogenesis 
The mechanisms leading to autoimmune attack of the hepatocytes are unknown, but several 
observations suggest that AIH is a multifactorial disease (Longhi et al, 2009). The 
histological pictures of interface hepatitis and immunohistochemical studies have identified, 
among the immune-reactive inflammatory cells, a large predominance of activated T 
lymphocytes positive for the CD4+ helper/inducer phenotype. The CD4+ T lymphocytes 
are believed to recognize one or more self antigens on the cell surface of the hepatocytes, 
thus triggering the autoimmune response. 
2.2.1 Autoantigen presentation 
The first step in an immune reaction is the presentation of the antigen to naive CD4+ T 
lymphocytes. The antigenic peptide is carried by professional antigen-presenting cells 
(APC) on their membrane within the binding groove of class II human leukocyte antigen 
(HLA) molecules. These HLA class II molecules are encoded in close proximity to HLA I 
and HLA III genes, configuring a number of ancestral haplotypes due to strong linkage 
disequilibrium among the HLA loci. The HLA class II molecules expressed on the 
membrane of APC are able to hold only short peptides of 13-23 amino acid residues, 
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which are the final product of the internalization and partial digestion by the APC of 
extracellular proteins. The recognition of the complex “HLA II-exogenous peptide” is 
restricted by the specificity of the T-cell receptor and hampered by ligand to ligand co-
stimulation. Consequently, HLA class II plays a central role in regulating CD4+ T helper 
activity. The functional site of HLA class II, the peptide binding groove, is hosted within 
the DRα  and DRβ polypeptidic chain, which composes together the DR heterodimers. 
Alleles of the DRβ locus are highly polymorphous and present three hypervariable regions 
encoding amino acid motifs. The consequence of this polymorphism is that each 
individual carries different DR molecules with different binding properties and affinities. 
Consequently, the nature and the structure of HLA class II polypeptidic chains, and 
especially of the DR molecules, critically affect both the nature and the alignment of the 
antigenic peptide and the affinity and avidity of the linkage between the antigen major 
histocompatibility complex (MHC) II and the T-cell receptor. Thus, the suitability of 
certain autoantigens to trigger an immune response is genetically determined and 
depends strictly on the genotypic asset of HLA class II. 
2.2.2 Genetic background 
In the Caucasian population, the HLA A1-B8-DR3 haplotype is associated to AIH-1 as 
well as with several autoimmune disorders. The HLA DR3 and DR4 haplotypes were 
identified as independent risk factors for AIH-1, whereas HLA DR2 was accounted to 
have a protective role. With the availability of high-resolution HLA-typing methods, the 
molecular basis of this association became investigable and the principal susceptibility 
allele for AIH-1 was recognized in DRB1*0301 (Czaja, 2000). This allele not only confers an 
increased risk to develop AIH-1, but also influences some features of the disease. Patients 
bearing DRB1*0301 in fact present at younger age, respond less favorably to corticosteroid 
treatment, carry a higher risk of relapse, and require liver transplantation more frequently 
for end-stage liver failure. Genetic predisposition to AIH-1 has, however, a relevant 
regional variation, and studies outside Europe and North America have found different 
susceptibility alleles at the DRB1 locus. In Japan, the prevalence of DR3 haplotype in the 
general population is very low and DR4 is the principal risk factor for AIH type. In an 
adult Brazilian mixed population with different percentages of whites, blacks, and 
Amerindians, a weak association with DRB1*1301 (DR6) was found, while in Mexicans of 
mixed ancestry, the primary HLA association is with DRB1*0404 as a part of the DR4 
serologic subset. 
Data concerning HLA typing in children with AIH-1 are scant. European children show the 
typical pattern for AIH-1 in Caucasoid patients, with a significant prevalence of DR3 
(DRB1*0301) and DR52a (DRB3*0101) and with a low prevalence of DR4. In a large 
Argentinean series, DR6 (DRB1*1301) was the primary susceptibility allele, with a secondary 
association with DRB1*0301, while HLA DRB1*1302, which differs by only one amino acid, 
showed a weak protective role. A study concerning a mixed Brazilian population with a 
prevalence of patients older than 16 years reported comparable results: DRB1*1301 was 
observed more frequently in children than in adults. A secondary association with 
DRB1*0301 was recorded in all age groups, but DRB1*1301 patients were significantly 
younger than the DRB*0301 counterpart. More recently, in an array of 50 families from 
France and Quebec, once more, the DRB1*1301 allele resulted as the primary genetic risk 
factor for AIH-1 in children. 
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Genetic background of AIH-2 has been poorly investigated to date because of the low 
prevalence of this form in adults. Two reports from Europe focused on the DRB1*03 and 
DQB1*02 alleles, whereas another study conducted in a German population reported an 
increased frequency of DRB1*07, DRB4*01, and DQB1*06. In a population from Brazil, 
composed for the large part by pediatric patients, a significant increase of DRB1*07, DRB4, 
and DQB1*02 was observed when compared with healthy controls. The last two alleles were 
in strong linkage disequilibrium with DRB1*07. Speculating on this data in comparison with 
the patterns of susceptibility showed in adult patients, we can argue that DRB1*1301 is a 
relevant risk factor peculiar to pediatric age and, interestingly, among adult patients it is 
associated with younger age. 
The DR4 family of alleles seems not to be implicated in children, whereas in adults they 
have been described as a marker of a mild, late-onset disease. This might explain the 
peculiar epidemiology of AIH-1 in Japan, where HLA DR3 has a very low prevalence in the 
general population and pediatric cases of AIH are rare.  
2.2.3 Autoantigens 
The autoimmune response, independently of the trigger, develops against one or more 
autoantigens  (Bogdanos, 2009). Recognition of these autoantigens might be the key factor in 
developing an etiologic-based therapy. Unfortunately, most of the antigens recognized by 
autoantibodies detected in AIH are either nonspecific or intracellular molecules and 
unlikely to be involved in breaking self-tolerance and provoking the emergence of liver-
infiltrating immunocytes. The most likely candidate autoantigens seem to be the 
asialoglycoprotein receptor (ASGP-R) for AIH-1 and CYP2D6 for AIH-2. The ASGP-R is an 
organ-specific molecule located in the membrane and with a prevalent periportal 
expression. Both peripheral and infiltrating lymphocytes taken from adults and children 
with AIH show a proliferative response to purified human ASGP-R and can induce 
autologous B-lymphocytes to produce anti-ASGP-R autoantibodies in vitro. A lack of T 
suppressing function specific for ASGP-R has been also reported both in patients and in 
their healthy relatives. This defect seems to reside in a subpopulation of CD4+ T-cells and it 
is inherited as an autosomal, non HLA-linked trait and it is corrigible by 
immunosuppressive therapy. Unfortunately, auto-reactivity against ASGP-R is not AIH-
specific and its pathogenetic role is far from being defined. 
Seven isoforms of cytochrome P450 are highly expressed in human liver: two major 
isoforms, CYP2C and CYP3A that account for 50% of total CYP expression and five minor 
isoforms, including CYP2D6. All these isoforms have been identified as LKM targets in 
different types of liver diseases such as autoimmune, viral, and drug-induced liver diseases. 
The likely molecular target of AIH-2, CYP2D6, is an intracellular enzyme active in phase I 
detoxification of several drugs. The CYP2D6 was extensively studied to map the most 
frequent epitopes in LKM-1. Several short sequences were identified and each of them was 
labeled, via gene bank searches, as cross-reacting with viral proteins, or human proteins 
involved in other autoimmune disorders. The sequence 193-212 of CYP2D6 is recognized by 
93% of the AIH-2 sera and 50% of the LKM-1/HCV-positive sera, and presents extensive 
cross-reaction with HCV and cytomegalovirus peptides. Furthermore, inhibition studies of 
the CYP2D6 enzymatic activity showed clearly that conformational epitopes exist and are 
functionally prevalent. By the effect of some cytokines, CYP2D6 can be expressed on 
hepatocyte surfaces, becoming a potential target for auto reactive T-cells. Several viruses 
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had been proposed as triggering factors in the pathogenesis of AIH such as measles virus, 
Epstein-Barr virus, hepatitis A virus, or herpes simplex virus. Molecular mimicry had been 
equally invoked between CYP2D6 and the IE 175 protein of herpes simplex virus, but 
presently none of these viruses is considered as a specific cause of AIH in genetically 
susceptible individuals. 
2.2.4 Autoimmune reaction as a defect of immune regulation 
High titers of antibodies against different microbial antigens are present in patients with 
AIH; this non antigen-specific defect, also present in first-degree relatives, is correctable 
both in vivo and in vitro by pharmacologic doses of corticosteroids and is related to a 
generic impairment of “T-cell suppression”. Children with this condition have low level 
of CD8-expressing T-cells, which segregate with the possession of HLA haplotype B8 
DR3. Furthermore, patients with AIH have been reported to have a specific defect in a 
subpopulation of T lymphocytes controlling the immune response to liver-specific 
antigens expressed on the hepatocyte membrane. More recently, a CD4+ T-cell subset 
expressing the interleukin 2 (IL-2) receptor, known as CD25 regulatory T-cells, have been 
found to be reduced in number at diagnosis of AIH. This CD4+ T-cell subset regulates the 
proliferation of auto-reactive T-cells through the release of immunoregulatory cytokines 
such as IL-10. 
2.3 Clinical features 
Autoimmune hepatitis is heterogeneous in nature and it is usually classified in two types 
according to the pattern of the autoantibody panel detected at the time of diagnosis ( 
Odièvre, 1983). Type 1 AIH is characterized by the presence of anti-smooth muscle antibody 
and/or antinuclear antibody and AIH-2 by the presence of anti-liver-kidney microsomal 
antibody type 1 and/or anti-liver cytosol type 1 antibody. The ratio of incidence of the two 
types in Europe is 2:1, while it is 7:1 or greater in America and in Japan. In Europe, AIH-2 
represents about 20% of new diagnoses of AIH, while in the USA AIH-2 represents only 5%.  
Differences between the two types consist in the epidemiologic distribution, genetic 
markers, and clinical presentation (table 1), which might underlie the different pathogenetic 
mechanism and include (Mieli Vergani & Vergani, 2009): 
• AIH-1 affects children and adults, while AIH-2 is almost exclusively a childhood 
disease; 
• Patients with AIH-2 are younger and have a higher tendency to present as an acute 
liver failure; 
• Hypergammaglobulinemia, which is quite typical of AIH-1, is moderate and 
occasionally absent in AIH-2; 
• AIH-2 progresses through “flares” of necrosis usually spontaneously regressing and 
this can explain why AIH-2  can be  characterized by transitory phases of mild 
histological activity; 
• AIH-2 is almost never associated to evidence of bile duct lesions, dissimilar to AIH- 1 
where different degrees of bile duct lesion are common; 
• Extrahepatic autoimmune disorders are reported in patients with both types of AIH 
and in first-degree relatives with a higher prevalence of autoimmune thyroid (Grave’s 
and Hashimoto diseases) and skin (vitiligo and alopecia) disorders in AIH-2.  
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 AIH type 1 AIH type 2 
Small ducts autoimmune 
sclerosing cholangitis 
Age of onset 
infancy and early 
childhood 
infancy and 
early childhood 
all ages 
Symptoms at onset 
Symptomatic acute 
hepatitis 
Symptomatic 
acute hepatitis 
Often related to the 
associated inflammatory 
bowel disease 
Cirrhosis at onset not frequent not frequent not frequent 
Hypergammaglobulinemia possible possible possible 
Biliary lesions absent absent constant 
Autoantibodies LKM1, LC1 LKM1, LC1 
ANA, SMA, p/cANCA, 
SLA 
Extrahepatic disorders 
except IBD 
Frequent Frequent possible 
Associated IBD Unusual Unusual frequent 
Response to 
immunosuppressive  
treatment 
usually good usually good possible 
w
w
w
.intechopen.com
 Liver Biopsy as a Useful Tool in the Management of Autoimmune Liver Diseases in Childhood 
 
271 
Despite this heterogeneity, available data suggest a similar outcome and a similar response 
to treatment. 
Beside these two main clinical-serological subtypes, in about 10% of patients AIH may 
present as a cryptogenic chronic hepatitis with the same demographic, biochemical, 
histological features and the same response to immunosuppressive therapy of both subtypes 
of AIH, but in absence of any recognizable autoantibody reactivity pattern. This entity 
recently described in adults as seronegative autoimmune hepatitis it has been also 
recognized in children. Recognition and treatment of SAIH are necessary to prevent 
progression to end-stage liver disease and liver biopsy in such patients play a pivotal role.   
Overall, there are three clinical patterns of disease onset: 
• The most frequent is indistinguishable from that of an acute viral hepatitis, with 
malaise, anorexia, nausea, vomiting, and abdominal pain followed by jaundice, dark 
urine, and pale stools. Some patients, particularly anti-LKM-1 positive, may develop 
acute liver failure with encephalopathy (Maggiore et al, 1990). Identifying autoimmune 
hepatitis as the etiology of acute liver failure is potentially important, because 
administering appropriate immunosuppressive therapy might avoid the need for liver 
transplantation. Even clinical and histological criteria of autoimmune acute liver failure 
have not been fully defined; liver histology may be particularly helpful in suggesting 
the diagnosis. 
• About 30% of patients, with a higher frequency for AIH type 1, have an insidious onset 
with an illness characterized by progressive fatigue, anorexia, weight loss, or a 
relapsing course with jaundice eventually followed by a spontaneous partial recovery, 
sometimes even a complete normalization of liver function tests, even if acute 
exacerbation is usually experienced within a few months (Maggiore et al 1993). Patients 
may progress with a fluctuating course lasting for several months/years before 
diagnosis (Maggiore et al 1984). Firm hepatomegaly, splenomegaly and signs of liver 
function impairment are, however, frequent and cirrhosis or severe fibrosis is often 
present at diagnosis. 
• Between 10-15% of patients may be completely asymptomatic when the underlying 
disease is accidentally discovered by the finding of hepatomegaly or by an increase of 
aminotransferase activity.  
• Rarely, AIH may present with bleeding from esophageal varices as a complication of 
portal hypertension, or with symptoms related to an associated extrahepatic 
autoimmune disorder such as chronic diarrhea, weight loss, and goiter. 
Autoimmune extrahepatic disorders are reported in about 30% of patients and include 
autoimmune thrombocytopenia, autoimmune hemolytic anemia, type 1 insulin-dependent, 
diabetes, autoimmune thyroiditis, vitiligo, cutaneous vasculitis, uveitis, glomerulonephritis, 
juvenile chronic arthritis, systemic lupus erythematosus, and Sjögren’s disease. Celiac 
disease, in particular, may be associated with all types of autoimmune liver disorders with a 
particular high frequency (Caprai et al, 2008). 
A form of AIH akin to AIH-2 affect some 20% of patients with autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). APECED is an 
autosomal-recessive disorder caused by mutations in the autoimmune regulator (AIRE1) 
gene, and is characterized by a variety of autoimmune diseases accompanied by chronic 
muco-cutaneous candidiasis. These disorders include hypoparathyroidism and autoimmune 
adrenalitis. The AIRE1 gene is highly expressed in the thymus and the protein encoded by 
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the gene is involved in clonal deletion of self-reactive T-cells.  AIRE1 monoallelic mutations 
have been reported also in a few children with severe AIH-2 and extrahepatic autoimmune 
disorders. 
2.4 Laboratory findings 
Besides the presence of specific autoantibodies that characterize the two types of AIH, 
abnormal laboratory findings exploring evidence of liver injury and/or abnormal liver 
function are frequent in AIH.  Serum aminotransferase activity, which is the most sensitive 
test of ongoing liver injury, is increased in all untreated patients, sometimes markedly, up to 
or more than 50-times the upper normal limit. Gamma glutamyltransferase (GGT) activity 
commonly exploring evidence of bile duct injury, may be normal or slightly elevated. A 
significant increase of GGT should lead to suspect relevant bile duct damage as in the case 
of autoimmune cholangitis or overlap syndrome. Total serum gamma globulins are elevated 
in about 80% of patients, sometimes markedly; the increase concerns particularly 
immunoglobulin G class. This feature is typical of AIH-1, but may be absent in young 
patients with AIH-2 presenting with acute onset. Partial or complete serum 
immunoglobulin class A deficiency and genetically determined low levels of C4 can be 
found and are more common in AIH-2. Serum albumin may be normal in the early phases 
of the disease, but it may be reduced in case of cirrhosis with liver insufficiency. Reduction 
of protrombin activity reflects the severity of liver function impairment together with the 
level of total bilirubin, in case of acute presentation with severe liver dysfunction.  
2.4.1 Autoantibodies 
Determination of traditional autoantibodies (ANA, SMA and LKM-1) is very helpful when 
diagnosing AIH (Krawitt, 2011). Their assessment is performed by indirect 
immunofluorescence (IF), a diagnostic technique, somewhat out of fashion because it is 
time-consuming and requires experienced technicians and laboratory physicians (Vergani et 
al, 2004). However, IF testing on murine tissue sections remains the gold standard for the 
detection ANA, SMA and LKM-1 reactivity. ANA fluorescence pattern, which in AIH is 
usually homogeneous, can be further characterized using Hep2 cells which are less specific 
when used as a screening. Both ANA and SMA are hallmarks of AIH-1, and they are usually 
present at high (≥ 1:100) titer and their presence is usually mutually exclusive.   
Rat stomach is commonly used as substrate to detect SMA: uniform staining of the 
muscolaris mucosae as well as staining of the blood vessels walls (V) and of the parietal cell is 
characteristic. In rat kidney tissue, a faint staining of the mesangial area of glomeruli (G) and 
of the brush border of proximal renal tubular cells (T) is also present. The “VG” and “VGT” 
are the most frequent IF staining pattern detected in AIH. Smooth muscle antigen is directed 
against structural components of the cytoskeleton such as actin, desmin, and troponin. The 
SMA reactivity in AIH is mostly directed against filamentous (F) actin, present in the 
hepatocytes as a part of the cytoskeleton in close proximity to the plasma membrane. Anti-
F-actin reactivity, which corresponds to the “VGT” IF pattern, is present in the majority of 
patients with AIH, especially children, even if its absence does not exclude the diagnosis of 
AIH (Maggiore et al, 1993). Antinuclear antibodies have various patterns of IF: 
homogeneous, the most common (60%), speckled (15-25%), and mixed 
homogeneous/speckled. Several nuclear antigens with a wide range of molecular weight 
were identified as a target of ANA reactivity. There is no evidence in ANA-positive AIH 
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patients of an association of a particular nuclear antigen with specific clinical manifestations 
of AIH or with treatment outcome. The IF ANA pattern is not counted on to have clinical 
importance and it could vary in the same patient during follow-up. The cut-off titer for the 
positivity of ANA is commonly indicated to be 1:40 in children. Our experience, however, 
suggests in clinical practice to raise the cut-off point to 1:100 to avoid over diagnosis due to 
low specificity of such autoantibody.  
Anti-LKM-1 serum reactivity defines AIH-2 (Maggiore et al, 1986). Anti-microsomal 
antibodies are a heterogeneous group, associated to a number of immune-mediated hepatic 
diseases such as drug-induced hepatitis, chronic viral hepatitis (HCV and HDV) and 
APECED. The distinctive IF pattern of LKM-1 on rodent liver and kidney sections is a 
diffuse cytoplasmic staining of microsome of hepatocytes and of the proximal renal tubular 
cells (P3 portion). A weak staining of the distal tubules is occasionally present and this can 
generate confusion with anti-mitochondrial antibody (AMA). Positivity for AMA in 
childhood patients should therefore be considered with caution since AMA-positive AIH or 
primary biliary cirrhosis are entities extremely rare in this age group. The LKM-1 target a 50 
kDa antigen identified as cytochrome P450 2D6 (CYP2D6) (Gueguen et al, 1988) and inhibits 
in vitro but not in vivo CYP2D6 activity. Also, LKM-1 can be present in a small proportion (5-
10%) of HCV-related hepatitis, even if the target epitopes are different. The role of LKM-1 
antibody in the pathogenesis of liver cell injury is debated. The recent demonstration that 
CYP2D6 can be expressed on liver cell surface and the finding that immunization in mice 
with human CYP2D6 can induce liver damage suggests that LKM-1 might play a role in 
inducing liver cell damage in AIH (Muratori et al, 2000).  
Anti-liver cell cytosol antibody 1 is an organ-specific autoantibody and its presence also 
characterizes AIH-2. It was identified by IF, immunodiffusion, and immunoblotting 
techniques and characteristically stains the cytoplasm of the rat hepatocytes in a 
homogeneous pattern, sparing the cellular layer around lobular central veins without 
staining of the proximal renal tubules (Martini et al, 1988 ).  Liver cytosol-1 antibodies 
recognize a 58-62 kDa liver-specific antigen identified as formiminotransferase 
cyclodeaminase  (Lapierre et al,  1999). Liver cytosol-1 can be present on its own as a sole 
autoantibody  (Bridoux-Henno et al, 2004 ), can be found associated with LKM-1 reactivity 
in about 50% of AIH-2, and occasionally it has also been described associated with anti-SMA 
at low titer and in adults with HCV-related chronic hepatitis. 
In 20-30% of adult patients lacking ANA, SMA, or LKM-1, the diagnosis of AIH can be 
suggested by the finding of other, less common autoantibodies such as anti-soluble liver 
antigen (SLA/LP) or anti-neutrophil cytoplasmic antibody (ANCA). None of these 
autoantibodies except SLA is specific for AIH since they are found either in several systemic 
autoimmune diseases, or in liver diseases of infectious etiology such as HCV infection. Anti-
soluble liver antigen is a non specie-specific, non organ-specific antibody currently assessed 
by immuno-enzymatic or radio immunological assays. The target antigen is likely to be a 50 
kDa 422-amino acid protein, identical to previous liver pancreas antigen. Soluble liver 
antigens are present in patients with AIH-1, AIH-2. Antibodies to SLA/LP are of a major 
diagnostic value for AIH-1, including overlap syndromes but are not found in association 
with anti-liver/kidney/microsome type 1 or antibodies to liver cytosol type 1. They are 
rarely present in other liver diseases such as hepatitis C and drug-induced hepatitis. 
Antineutrophil cytoplasmic antibodies have a heterogeneous pattern of target antigens and 
are commonly distinguished as cytoplasmic (cANCA), perinuclear (pANCA) and atypical 
perinuclear (apANCA). They have been described in AIH-1 and in ASC patients with all 
types of pattern, while they are virtually absent in AIH-2. 
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Once diagnosis is made, autoantibody reactivity fluctuates during treatment, reducing in 
titer in case of remission, but also independently. Autoantibody status is not predictive of 
laboratory and histological features; moreover, high serum titers at presentation do not 
identify patients with more aggressive disease or different treatment outcomes. Finally, the 
disappearance of autoantibodies is not predictive of low risk of relapse during treatment or 
of sustained remission in case of stopping the treatment.  
2.5 Histology 
The histological hallmark of AIH is “interface hepatitis”, defined as a dense, inflammatory 
infiltrate of mononuclear cells, lymphocytes (mainly T helper and natural killer), plasma 
cells and activated macrophages infiltrating the portal tract, invading the adjacent 
parenchyma and surrounding apoptotic hepatocytes with erosion of the limiting plate 
(Figure 1). Interface hepatitis may be present in other inflammatory liver diseases of 
different etiologies (viral, drug-induced, etc.) and this peculiar histological picture is to be 
properly integrated in clinical and biochemical setting.   
Plasmacells are considered another significant histopathological hallmark of autoimmune 
disease; they may be diffusely evident in interface and lobular hepatitis areas, but in about 
one third of the cases plasmacells are patchy localized within liver parenchyma.  
A considerable amount of eosinophilic granulocytes is often present within the portal 
infiltrate, especially in patients with co-existent celiac disease (Caprai et al, 2008).  Most 
patients with autoimmune hepatitis have parenchymal complications of chronic 
inflammation such as severe fibrosis and about a third of them are already cirrhotic at 
presentation. In children, this proportion seems to be even higher. Only patients with very 
acute presentation may lack features of chronic hepatitis and fibrosis. Cirrhosis in 
autoimmune hepatitis is often macronodular, and may easily be overlooked by 
percutaneous liver biopsy. Anyway a confident histological diagnosis of cirrhosis should be 
proposed only in case of well-defined nodular fibrotic transformation, mainly in cases with 
severe features of activity, as massive necrosis with parenchymal collapse may lead to a 
nodular appearance of the liver.  Laparoscopy, a minimally invasive technique with the 
currently available very small diameter endoscopes, is helpful in making a diagnosis of 
cirrhosis in autoimmune hepatitis, as cirrhosis maybe overlooked in up to 50% of cases 
without macroscopic assessment of the liver. Diagnosis of cirrhosis may influence the choice 
and dose of the immunosuppressive agents prescribed, has prognostic implications, and 
forms the basis for regular screening for complications of cirrhosis, such as esophageal 
varices bleeding. 
Liver histology plays a major role in two particularly challenging diagnostic conditions: the 
AIH with very acute onset and the seronegative AIH. In case of very acute onset, the 
inflammatory liver injury, in contrast to classical autoimmune hepatitis, predominates in the 
centrilobular zone and it is often associated with reticular collapse. In such cases four 
features may suggest an autoimmune pathogenesis: the presence of massive/submassive 
hepatic necrosis (Figure 2), the presence of lymphoid follicles within portal tracts (Figure 3), 
a plasma cell-enriched inflammatory infiltrate and central perivenulitis. Ductular 
(intermediate) hepatocytes are considered a reactive/regenerative  response to injury and 
more commonly present in case of massive/submassive necrosis serving as hepatic 
progenitor cells, and could be seen as cytokeratin 7 (CK7)-positive hepatocytes in 
immunohistochemistry. In case of seronegative autoimmune hepatitis the liver histology 
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represent an invaluable diagnostic tool showing features suggesting an autoimmune 
pathogenesis. Centrilobular changes are prominent due to the high frequency of acute icteric 
onset. 
Bile duct inflammatory changes are not considered a typical lesion of autoimmune hepatitis. 
They can be found in limited proportion (about 25% of patients with AIH-1) in form of 
destructive or not destructive cholangitis and ductopenia. Patients with and without bile 
duct changes had similar laboratory findings but diagnostic scores for AIH are lower in case 
of  bile duct damage. Patients with destructive cholangitis and/or ductopenia respond as 
well to therapy as patients with nondestructive cholangitis, and outcome is similar to those 
of patients without biliary changes. 
2.6 Diagnosis 
The diagnosis of AIH in children can be easy when all the typical hallmarks of the disease 
are present, such as the presence of another autoimmune disease in the same patient, 
hypergammaglobulinemia of IgG type with the demonstration of specific autoantibodies 
and a suggestive histology. However, in some patients the diagnosis be challenging, and in 
this case it is usually made by a combination of clinical, serologic, and histologic criteria and 
by the exclusion of other possible known causes of severe hepatic disease, such as chronic  
hepatotropic virus infections and Wilson’s disease, by appropriate tests.  
 
 
Fig. 1. Presence of dense portal and periportal inflammatory infiltrate with lymphocytes, 
histiocytes, neutrophilic and eosinophilic granulocytes and plasma cells with interface 
activity. 
Even if histopathology features pathognomonic of autoimmune hepatitis are lacking, liver 
histology should be always performed at diagnosis if hemostasis allows it. The characteristic 
lesion of “interface hepatitis”, characterized by a predominantly lymphoplasmacytic, 
necroinflammatory, and periportal infiltrate with or without lobular involvement should 
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suggest the diagnosis. Other suggestive features include the presence of portal-portal or 
central-portal bridging necrosis, formation of liver cell rosettes and the presence of nodular 
regeneration, even in the early stages, in the most severe cases. Storage of metals like iron, 
copper, or intracellular proteins have to be excluded by appropriate histochemical 
techniques.  
Features of biliary damage are usually absent or limited. In case of absence of typical serum 
autoantibodies, it is mandatory to send a serum sample to a reference laboratory to 
investigate the presence of autoantibodies not routinely assessed such as ANCA or LC-1. If 
doubt persists, in case of severe cryptogenetic inflammatory disease, once Wilson’s disease 
is excluded, it is advisable to attempt an immunosuppressive treatment for at least six weeks 
to evaluate the sensitivity of the disease to immunosuppressive therapy.  
To help the diagnosis of autoimmune hepatitis, a panel of physicians and pathologists has 
published a descriptive set of criteria to classify patients as having either “definite” or 
“probable” autoimmune hepatitis. This scoring system has been used in a large number of 
studies and it has shown a good sensibility (89.9%) but a low specificity (60.8%), particularly 
in cases of immune-mediated biliary diseases like autoimmune cholangitis or primary 
biliary cirrhosis, which often score as a “probable” autoimmune hepatitis. In 1999 the score 
was reviewed; however, this scoring system still remains more adapted to adulthood than to 
childhood since some items, for example, concerning the use of the alkaline 
phosphatase/aminotransferase ratio due to the low discriminating role of this enzyme in 
childhood in exploring bile duct damage or alcohol consumption. 
 
 
Fig. 2. Submassive necrosis with panlobular and portal inflammatory infiltrate with CD3 
and CD20 positive lymphocyte plasmacells and polymorphonuclear eosinophils and 
neutrophils in a girl with AIH-1 with marked hypergammaglobulinemia and acute onset. 
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. 
Fig. 3. Lymphocytic infiltrate shaped as lymphoid follicles surrounding two biliary 
structures with features of destructive cholangitis and marked ductular proliferation (CK7 
immunostaining). 
2.7 Management 
Currently, the most effective therapy for AIH is immunosuppression. The degree of 
response to treatment depends on the severity of the disease at presentation. Standard 
treatment includes prednisolone as monotherapy or a combination of prednisone and 
azathioprine. Prednisone or prednisolone is used at a dose of 2 mg/kg/day (maximum 
daily dose of 60 mg in adolescents), and azathioprine is prescribed starting from 1 
mg/kg/day up to a maximum 2.5 mg/kg/day. Combination therapy from the start of 
treatment is generally preferred because of the “steroid-sparring” effect of azathioprine that 
allows reducing the steroid dose more rapidly, avoiding the severe side effects related to 
their prolonged use at high doses (Maggiore et al, 1984). 
2.7.1 Efficacy of the treatment 
The first goal of the treatment in AIH is to induce a complete remission of the clinical signs 
(jaundice, hepatomegaly, and/or splenomegaly) and of the biochemical “activity” of the 
disease (aminotransferases, gamma globulins). Treatment generally is associated with a 
measurable clinical and laboratory response within 6-10 weeks that is usually followed by 
restoration of liver function, when impaired at onset, as demonstrated by the normalization 
of protrombin activity (Maggiore et al, 1984). Once the response to treatment is established, 
prednisone doses are gradually decreased, being aware, however, that complete 
normalization of biochemical parameters takes a longer period of from 6-9 months. Different 
therapeutic schedules of treatment discontinuation exist; however, discontinuation of 
therapy should be tailored for individual patients in relation to their characteristics. The 
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shift to alternate-day use of corticosteroids is very suitable as soon as possible because it is 
associated with a lower incidence of side effects, particularly concerning growth, without 
increasing the risk of relapse (Maggiore et al, 1984). About 10% of cases, with severe liver 
function impairment at onset, however, deteriorate despite compliance to therapy. In these 
cases a “rescue” immunosuppressive therapy, with 2 mg/kg/day of  steroids or  1 mg/kg 
day plus  cyclosporine to a target blood level of 200 ± 50 ng/mL has been proven successful 
in 90% of patients  in a mean period of 3 weeks (Cuarterolo et al, 2011). Eventually,  the 
adjunction of cyclosporin  as a third immunosuppressant agent  or the substitution of 
azathioprine with mycophenolate mofetil should be assayed  (Schramm C & Lohse AW, 
2011). Treatment failure should lead to promptly discuss of the opportunity of an early liver 
transplantation. 
2.7.2 Sustained response 
Once complete remission is achieved, the goal of treatment becomes to maintain remission 
and to prevent relapses. The dose of prednisone is to be reduced further to the lowest dose 
compatible with a clinical and biochemical remission (strictly normal aminotransferases and 
gamma globulins levels). Small doses of prednisone on alternate-day schedule combined 
with azathioprine are in fact effective in maintaining remission. Once remission is achieved, 
a relapse can occur and in most cases it is related to inappropriate patient compliance to the 
prescribed treatment. To demonstrate histologic remission by a liver biopsy in a patient with 
long-standing, complete biochemical remission is a question of debate since histologic 
remission is not absolutely predictive of no risk of relapse. Hepatic fibrosis progresses only 
in a minority of patients who are compliant to treatment and who maintain a persistent 
remission. In some cases, fibrosis can even diminish during treatment. 
2.7.3 Duration of treatment 
No evidence-based data exist on the optimal duration of immunosuppressive treatment. 
Relapse is frequent if treatment is withdrawn within the first two years. Current experience 
suggests that sustained remission should be maintained for at least five years, then, in the 
case of treatment combining prednisone and azathioprine, prednisone should be stopped 
during the sixth year, maintaining a sustained remission on azathioprine monotherapy for 
at least another year. Azathioprine monotherapy, as in adults, reduces the likelihood of 
relapse and maintains sustained remission in most patients with AIH, independent of its 
serological type. Absence of serum autoantibodies is not predictive of an absence of relapse; 
however, a sharp increase of the titer of autoantibodies prompts caution in reducing the 
immunosuppression. 
2.7.4 Side effects of treatment 
Combination therapy is associated with side effects, mostly caused by prednisone that 
produces increased appetite, moderate weight increase, sometimes marked and a transitory 
reduction of height growth. Severe side effects are less frequent in specialized centers, but 
frequent in less experienced centers and include obesity, growth failure, severe cosmetic 
changes, cutaneous striae, vertebral collapse, hyperglycemia, cataracts responsible for visual 
impairment, and psychosis. Azathioprine is rarely responsible for severe side effects such as 
cytopenia necessitating a dosage reduction. Teratogenicity and oncogenicity issues of 
azathioprine in humans have not been conclusively demonstrated. However, pregnancy 
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should be ruled out in adolescent girls before starting treatment since azathioprine therapy 
during pregnancy cannot be recommended. 
2.7.5 Alternative treatments 
Failure to respond to conventional treatment or severe side effects of corticosteroids are 
clear indications for the use of cyclosporine A. Cyclosporine therapy is effective in inducing 
remission in patients with AIH at a median dose of 5 mg/kg/day to obtain serum 
cyclosporine initial concentration in the range of 200-250 ng/ml even if lower levels are 
often equally effective. Side effects of cyclosporine treatment are few, well tolerated, and 
disappear after reduction of the dose (Sciveres et al 2004). Once remission is achieved, 
treatment may be continued at lower doses or patients may be shifted to conventional 
treatment. Mycophenolate mofetil (MMF, 20 mg/kg twice a day) has been successfully 
employed in addition to steroids in patients who either did not tolerate azathioprine or did 
not respond to standard therapy, suggesting that it may represent another alternative 
strategy of treatment. Side effects of MMF include headache, diarrhea, dizziness, hair loss, 
and neutropenia.  
Liver transplantation is the treatment option of choice in end-stage AIH or in patients with 
acute severe/fulminant onset who do not respond to rescue immunosuppression. The 5-
year posttransplant survival for these AIH-patients  is  86% and patient and graft survival, 
infectious and metabolic complications, and retransplantation rates did not differ between 
AIH and non-AIH patients (Martin et al 2011). The higher risk for late acute rejection and 
the greater degree of immunosuppression needed does not compromise outcomes of liver 
transplantation for AIH.  
2.7.6 Long-term prognosis 
The long-term prognosis of children with AIH remains uncertain. A sustained remission can 
be maintained in most patients, without notable side effects, with low-dose 
immunosuppression. A limited number of patients maintain a sustained remission once the 
treatment is stopped. Some patients with cirrhosis, in the absence of an evident relapse of 
the disease, may develop progressive liver insufficiency and need liver transplantation.  
3. Autoimmune bile duct disorders 
Autoimmune bile duct damage includes primary biliary cirrhosis in adults, autoimmune 
cholangitis and autoimmune overlap syndrome in adults and children. Since this chapter is 
devoted to autoimmune disorders in childhood PBC will not be examined. 
3.1 Autoimmune cholangitis (AIC) 
Autoimmune cholangitis is a chronic, immune-mediated, cholestatic disease of uncertain 
etiology, characterized by progressive inflammatory damage of intra and extrahepatic bile 
ducts resulting in obliterative fibrosis and destruction of small bile ducts and fibrosclerotic 
lesions of large bile ducts. Autoimmune cholangitis (AIC) may be distinguished in two main 
entities: the more traditional form, the so-called Primary Sclerosing Cholangitis (PSC), a 
chronic and diffuse inflammatory cholangiopathy  potentially involving all orders of intra 
and extrahepatic  bile ducts, characterized by radiographically visible biliary stricture and 
dilations of large and medium size  bile ducts and a variant form with a damage at least 
initially limited to small bile ducts, the so- called small duct sclerosing cholangitis, (SDSC). 
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In this form, biliary imaging explored both endoscopic cholangiography or magnetic 
resonance is normal or present only minor abnormalities. PSC is more common and typical 
of adulthood, usually progresses to cirrhosis and liver failure and carries an increased risk 
of cholangiocarcinoma. SDSC is more typical of childhood, and diagnosis may be suspected 
only on clinical, biochemical, and histologic features showing evidence of biliary 
inflammatory injury. 
3.1.2 Autoimmune (primary) sclerosing cholangitis (PSC) 
Autoimmune sclerosing cholangitis is also defined as primary sclerosing cholangitis (PSC) 
to be distinguished by secondary forms where a wide range of insults may produce similar 
cholangiographic imaging pattern. Secondary sclerosing cholangitis (SSC) is thought to 
develop as a consequence of known injuries or secondary to pathological processes of the 
biliary tree. The most frequently described causes of SSC are longstanding biliary 
obstruction, surgical or blunt abdominal trauma to the bile duct, ischemic injury to the 
biliary tree, intra-arterial chemotherapy, portal biliopathy, eosinophilic and/or mast cell 
cholangitis, recurrent pyogenic cholangitis, primary immune deficiency, and AIDS-related 
cholangiopathy. PSC can usually be differentiated on the basis of patient’s history and the 
strong association of PSC with inflammatory bowel disease (IBD).  
PSC is a rare disease, the true incidence and prevalence of PSC in children is grossly 
underestimated: recent studies suggest a mean annual incidence rate of 0.23/100,000 
compared to 0.77 cases per 100,000 person-year in adults. The incidence of PSC is similar in 
North American and European countries, but it continues to increase over time, this disease 
being diagnosed more frequently also in children and adolescents because of increased 
awareness of this condition and of the widespread use of noninvasive biliary imaging.  
3.1.2.1 Pathogenesis 
The etiology and pathogenesis of PSC remain very poorly understood. As the disease is 
associated with autoantibodies and peculiar HLA haplotypes as well as being closely 
related to IBD, it would appear to be immune mediated. An autoimmune mediated 
destructive process is also suggested by lymphocytic infiltration into areas of portal 
damage.  PSC is not however a classical autoimmune disease, as it occurs with a slight 
male predominance compared with the typical female predominance found in classical 
autoimmune liver diseases such as PBC and AIH. Moreover, PSC does not have the 
characteristic response to immunosuppressive treatment as seen in classical autoimmune 
diseases. Circumstantial evidence that PSC may be immune mediated comes from the 
independent association of PSC with a number of autoimmune diseases. Simultaneous or 
sequential occurrence of PSC and AIH has been described in both adult and pediatric 
populations. In general, PSC in children is characterized by more pronounced 
autoimmune features with a possible overlap with AIH. Serum autoantibodies and in 
particular, anti-neutrophil cytoplasmic antibodies (ANCA) are largely present in the 
serum of patients with PSC. They are however not specific for PSC and are also found in 
AIH. These ANCA may have atypical features distinct from perinuclear-staining anti-
neutrophil cytoplasmic antibody (p-ANCA) and by cytoplasmic-staining anti-neutrophil 
cytoplasmic antibody (c-ANCA). The target antigen for these atypical ANCA is probably 
a neutrophil nuclear envelope protein. Some authors have suggested that the term p-
ANNA is therefore more appropriate as the recognized antigen is not cytoplasmic but 
originating in the nuclear membrane. The importance of these autoantibodies in the 
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development of PSC is unknown, but current evidence suggests that they are unlikely to 
play a role in the pathogenesis of PSC. A high proportion of non-specific autoantibodies 
in addition to p-ANNA are found in patients with PSC, they are of unclear relevance and 
unhelpful in diagnosis. They include anti-nuclear antibodies anti-smooth muscle 
antibody, and anti-cardiolipin antibodies without however a demonstrated association 
with thrombotic disease. 
Association studies have identified various HLA molecules and other immunoregulatory 
genes as determinants of disease susceptibility and progression in PSC. There is an increased 
frequency of HLA B8 and DR3 (HLA DRB1*0301) in PSC. HLA B8 and DR3 are in linkage 
disequilibrium and this haplotype is also associated with several organ specific autoimmune 
diseases including AIH-1, diabetes mellitus, myasthenia gravis and thyrotoxicosis.  
There is a T cell predominant portal infiltrate in PSC although the relative proportions and 
importance of the CD4 and CD8 cells are not known. CD4 cells are seen more commonly in 
the portal tracts and CD8 cells predominate in areas of interface hepatitis, when present. The 
cell infiltrate may change as the disease progresses. These cells are functional and are likely 
to be involved in the pathogenesis of disease.  
PSC is strongly linked to IBD but it also runs a course independent from the bowel 
disease since the disease can develop many years after colectomy. It has been suggested 
that T lymphocytes generated in the gut during active inflammation persist as long-lived 
memory cells and undergo enterohepatic circulation and can then trigger an 
inflammatory response in the liver when activated by an appropriate stimulus. The nature 
of the stimulus remains unclear; possibilities include hepatic expression of the original 
priming antigen or possibly mediation solely by the aberrant expression of gut specific 
adhesion molecules and chemokines. Bacterial antigens may act as molecular mimics in 
genetically susceptible individuals and cause an immune reaction responsible for 
initiating PSC. The bacteria are able to get through gut walls made permeable by colonic 
inflammation; chemokines and cytokines are then released from Kupffer cells in the liver 
attracting macrophages, monocytes, lymphocytes, activated neutrophils and fibroblasts to 
the portal tracts. 
Finally, defects in the hepatobiliary transport system and in particular, in knockout mice for 
the Mdr2 (Abcb4) gene, which corresponds to human MDR3/ABCB4 gene defects, 
spontaneously develop sclerosing cholangitis with features similar to human PSC. A non-
functional ABCB4 protein leads to the formation of a “toxic” bile with increased 
concentration of free, non-micellar bile acids which cause cholangiocyte injury, 
pericholangitis, periductal fibrosis and, eventually, sclerosing cholangitis. Studies in PSC 
patients, however, did not find ABCB4 mutations. 
In summary, immune mechanisms play an important role in the pathogenesis of PSC, 
although it remains unclear whether it is a classical autoimmune disease. There are strong 
major histocompatibility complex genetic associations including HLA molecules. HLA 
haplotypes however do not account for all the genetic susceptibility in the development of 
PSC and there is uncertainty about the importance of genes outside this region. Bacterial 
antigens may act as molecular mimics in hosts who are genetically susceptible and 
therefore cause an immune reaction leading to PSC initiation. Lymphocytes may move 
from the inflamed gut in IBD via the enterohepatic circulation and cause inflammation of 
the liver when activated by a specific stimulus such as bacterially derived antigens. 
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3.1.2.2 Clinical features 
The mean age at diagnosis of PSC in the pediatric population is approximately 13 years 
with a slight (2:1) predominance in males,  but there are an increased number of earlier 
diagnoses in the first decade of life (Feldstein , 2003). PSC is strictly associated with an  
inflammatory bowel disease (IBD) reaching more than 80% of cases, while, only 2 -7.5% of 
children or adolescents affected by IBD develop sclerosing cholangitis (Miloh 2009). This 
form of IBD predominantly has the features of an ulcerative colitis and in a minority of a 
Crohn’s colitis. A distinctive IBD phenotype, consisting of a prevalence of diffuse colonic 
involvement (pancolitis), with however a less active disease and even asymptomatic in 
about 10% of cases; with eventual rectal sparing and backwash ileitis, but with an 
increased risk in the long term of colonic adenocarcinoma has been suggested (Loftus, 
2005). The diagnosis of IBD may precede or closely follow the onset of PSC. A prior 
history of abdominal pain, diarrhea, and eventually blood in stools is frequently reported 
by patients or their parents. Two thirds of children who have PSC are symptomatic at the 
time of diagnosis and the most frequent initial symptoms are related to the IBD or to a 
generalized inflammatory process. The abdominal pain is fluctuant, whereas fatigue is 
progressive and usually followed by anorexia and weight loss. Signs or symptoms 
directly related to the liver disease are rare, particularly in younger patients, and include 
hepatomegaly, splenomegaly, jaundice, and pruritus. Frequently the disease is discovered 
because of an occasional finding of increased aminotransferase level without any sign or 
symptom. The association with other extrahepatic autoimmune disorders, such as 
autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, Sjögren’s 
syndrome, and celiac disease, is less frequent than in AIH, but is reported in up to 25% of 
cases. 
3.1.2.3 Laboratory findings 
Although there are no specific laboratory features specific of PSC, elevated serum GGT 
activity is almost always present in these children and reflects the presence of ongoing 
bile duct injury (Feldstein, 2003). Serum aminotransferase activity is generally elevated in 
most patients, but the increase of these enzymes is not specific. Serum alkaline 
phosphatase levels are not as helpful in childhood because of the wide range of normal 
values for this enzyme during pediatric age, resulting from the increase of bone formation 
related to growth. Total bilirubin concentration is usually within a normal range in most 
patients, and signs of hepatic failure are unusual at diagnosis. An increased direct 
bilirubin level usually characterizes more severe, long-lasting forms with evident 
macroscopic fibrosclerotic lesions of bile ducts and cirrhosis. On the other hand, jaundice 
may be transient, secondary to bacterial cholangitis, which can be recurrent and could 
even finally represent an indication for liver transplantation. Thrombocytopenia and 
diminished white blood cell count secondary to portal hypertension due to hypersplenism 
can found in children with splenomegaly. Elevated IgG levels are found in 70% of 
children with PSC, and circulating autoantibodies that usually characterize AIH-1, such as 
ANA and/or SMA, are detected in serum of more than 80% of patients. Antineutrophil 
cytoplasmic antibody, with staining mainly but not exclusively in the periphery of the 
nucleus, is usually found by indirect IF. Anti-LKM-1 is practically never detected in these 
patients. 
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Fig. 4. Autoimmune cholangitis. An intrahepatic bile duct surrounded by an inflammatory 
infiltrate and ductal and periductal fibrosis. 
3.1.2.4  Histology 
In patients with PSC, percutaneous liver biopsy documents the presence of an inflammatory 
and/or fibrotic cholangiopathy (Figure 4) with progressive damage, atrophy and ultimately 
loss of small size bile ducts (ductopenia) (Figure 5). Edema and fibrosis around the 
interlobular bile ducts progressing to concentric periductal fibrosis (‘onion-skinning’) ( 
Figure 6), narrowing , obliteration of the small bile ducts, leaving a bile duct scar may be 
considered the main histologic feature of PSC, although may be missed in the liver sample 
as it is a focal histological feature. However, often only lesions of acute cholangitis are 
present, such as infiltration and destruction of biliary epithelium (Figure 6 B) with the 
finding of lymphoid folliculi or even granuloma, usually encompassing a bile duct. 
Inflammatory infiltrate around the bile duct is polymorphous mainly with lymphocytes, 
histiocytes; however a significant number of eosinophils can be present around bile duct 
and in the colonic cryptae in case of associated IBD (figure 7).  
Bridging fibrosis is frequent at diagnosis while typical lesions are present only in a limited 
number of patients with advanced fibrosis and more frequently findings are those of an 
aspecific cholangiopathy with ductular proliferation and loss of very small bile ducts. Septal 
fibrosis or cirrhosis is found in the initial liver biopsy of more than half of newly diagnosed 
children with PSC. An inflammatory infiltrate ranging from a mixture of lymphocytes and 
polymorphonuclear cells to a lymphoplasmacytic infiltrate with the features of interface 
hepatitis can be observed in about a third of patients. These features characterize the overlap 
syndrome. In advance disease, liver parenchyma show features of long standing cholestasis, 
i.e positive immunostaining to biliary-type citocheratin 7  and feathery degeneration of liver 
cells cytoplasm. 
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Fig. 5. Autoimmune cholangitis. A concentric fibrotic scar obliterating an intrahepatic bile 
duct. 
 
. 
Fig. 6. Autoimmune cholangitis. An intrahepatic bile duct surrounded by concentric 
periductal fibrosis (‘onion-skinning’). 
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3.1.2.5 Biliary imaging 
Visualization of intra and extrahepatic bile ducts by direct opacification of the biliary tree or 
by magnetic resonance (MR) cholangiopancreatography is an essential part of the diagnostic 
workup. Until recently, endoscopic retrograde cholangiography or transhepatic, 
transcholecystic, percutaneous cholangiography were used to visualize the biliary tree. 
Currently, MRI cholangiopancreatography provides an excellent quality of resolution for 
imaging intrahepatic and extrahepatic bile ducts in older children. Abnormal features 
observed include duct wall irregularities, strictures, irregular dilations, and beading 
resulting in the characteristic “bead-on-a-string” appearance (Figures 7 and 8). Lesions 
restricted to the intrahepatic branches are found in 30-40% of patients, whereas 
abnormalities limited exclusively to the extrahepatic ducts are rare. Cholelithiasis may be 
present, with the majority of patients being asymptomatic. 
 
 
Fig. 7. Autoimmune cholangitis. Inflammatory portal fibrosis with destructive ductular 
lesions and biliary proliferation without ductopenia 
3.1.2.6 Diagnosis 
Suspicion of PSC should arise when a patient presents with signs or symptoms of chronic 
liver disease, such as hepatomegaly, splenomegaly, stellar angiomas, palmar erythema, 
fatigue (more frequent in adolescents), anorexia, pruritus, or jaundice. The most common 
laboratory finding is an increase of the serum GGT activity. The possibility of PSC should be 
considered in any patient who has IBD and an increased liver enzyme serum activity, 
particularly if laboratory features suggesting cholestasis or symptoms or signs of chronic 
liver disease are present. Definitive diagnosis requires a liver biopsy and a biliary imaging. 
The diagnosis may be challenging in patients asymptomatic who do not have 
autoantibodies and hypergammaglobulinemia. In these patients, liver histology and the 
presence of an associated IBD may suggest the diagnosis. The differential diagnosis of PSC 
should include other causes of liver injury reported in patients who have IBD, including 
those such as drug-induced liver damage. 
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Fig. 8. Inflammatory bowel disease associated with Autoimmune cholangitis. Eosinophilic 
cryptitis  
In children who have ulcerative colitis and who have abnormal liver laboratory tests, a liver 
biopsy and a biliary imaging are usually indicated. Moreover, distinction between PSC and 
AIH-1 is not always easy. Traditionally, AIH and PSC are regarded as separate disease 
entities, but recently it was hypothesized that both diseases are part of the same process. 
 
 
Fig. 9. Endoscopic cholangiopancreatography showing irregular intrahepatic bile ducts with 
stenosis and dilation prevalent in left liver sections. 
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This condition corresponding to the overlap syndrome, which would encompass both PSC 
and AIH, may respond satisfactorily to immunosuppressive therapy. In fact, approximately 
50% of children with features of autoimmune liver disease present cholangiographic 
features typical of sclerosing cholangitis, though generally less advanced than those 
observed in adult patients with sclerosing cholangitis. All these patients present with the 
clinical features of typical AIH, many do not have typical histologic evidence of fibro-
obliterative bile duct damage on liver biopsy, and virtually all have the autoantibody 
pattern of AIH-1 
3.1.2.7 Management and prognosis 
Children with PSC have a significantly shorter survival than the expected for age-matched 
general population. Many children with PSC progress to end-stage liver disease with the 
consequent need for liver transplantation. Currently, no specific therapy is clearly 
standardized for PSC. Patients with PSC seem to have a more severe prognosis than those 
who have bile duct lesion limited to fourth order bile ducts (small duct sclerosing 
cholangitis, SDSC). Lesions of the large bile ducts and the consequent obstruction of bile 
flow contribute to the rapid progression of liver injury.  
Treatment with ursodeoxycholic acid leads to improvement of biochemical tests in most 
patients, but does not seem to affect survival in children or adults. One third of newly 
diagnosed patients have biochemical signs of inflammation as well as interface hepatitis at 
liver biopsy. Immunosuppressive therapy is not effective in adults with PSC, even if there is 
increasing evidences of some benefit in adults and children with SDSC. However, in these 
cases corticosteroids and azathioprine are frequently administered. No impact on long term 
outcome has been reported with these drugs in small pediatric series or in larger adult 
series. This lack of improvement in outcome occurs despite a good control of the 
inflammatory process. Stabilization or even regression of the cholangiographic lesions has 
been however observed, however, in half of patients treated after a median follow-up of 
four years. Immunosuppressant drugs are indicated in the frequent occurrence of overlap 
syndrome and it should be considered that anti-inflammatory and immunosuppressive 
drugs administered to maintain remission of associated IBD might interfere with the natural 
history of PSC, particularly in children. It can be speculated that the duration of the 
inflammatory process and development of fibrosis in the bile ducts before diagnosis 
influence the outcome. The overall median survival rate without liver transplantation is 
approximately 12 years in children who have PSC. A younger age at onset and significant 
portal hypertension are clinical variables associated with shorter survival in children.  
Surgical, endoscopic, or radiologic dilatation of bile duct strictures has been attempted in 
some patients who have PSC. Although transitory good results have been reported with this 
intervention, there seems to be no effect on long-term outcome. Any invasive procedure in 
these children can be complicated by bacterial cholangitis that would be difficult to treat, 
given the abnormal bile flow. Complications caused by chronic decrease in bile flow could 
be prevented with adequate nutritional support, including administration of liposoluble 
vitamins. Dominant strictures in PSC with significant cholestasis should be treated with 
balloon dilatation. Some patients also appear to benefit from short-term stenting. No 
randomized, prospective controlled trials have been performed to assess the efficacy of 
endoscopic treatment in PSC, and the application is presently performed based on 
individual assessment of each patient. Complications secondary to portal hypertension or 
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recurrent bacterial cholangitis can be considered possible indications for liver 
transplantation even if liver function is somewhat preserved 
Liver transplantation is the only therapeutic option for a child who has PSC, cirrhosis, and 
signs of liver failure. However, retransplantation rates are higher for patients with PSC than 
other diagnoses with a 25% recurrence rate in transplanted liver. An increased risk of acute 
cellular rejection in PSC has been demonstrated in several series, it is not clear whether PSC 
patients are particularly at risk or whether the risk is related to autoimmune liver disease in 
general. Furthermore, there is an increased risk of acute rejection in patients with pre-
transplant IBD as compared with patients without IBD and the risk of chronic rejection also 
seems to be higher in PSC patients with IBD. 
Recently prolonged treatment with oral vancomycin has been shown may be beneficial in 
difficult-to-treat PSC associated with inflammatory bowel disease. 
An increased incidence of colorectal neoplasia has been described in adult patients who 
have PSC-related IBD. This complication is the most frequent cause of death after liver 
transplantation in patients who have ASC. Cholangiocarcinoma may complicate PSC in 
adults, and is significantly more common in patients who have colorectal neoplasia. 
3.1.3 Autoimmune overlap syndrome  
Overlap syndrome in children and adolescents concerns only autoimmune hepatitis and 
autoimmune cholangitis features and includes patients within the spectrum of autoimmune 
liver diseases presenting with the characteristics of both PSC or SDSC and AIH. AIH and 
AIC are not homogeneous disorders and patients within each diagnosis may present with a 
range of clinical, biochemical, serological, and histological findings. However, the diagnosis 
of overlap syndrome should not be overlooked; certainly AIH should not be diagnosed in 
presence of definite bile duct pathology, but some coincidental biliary injury may be 
observed. The presence of some degree of biliary involvement in AIH should therefore not 
necessarily lead to a change in diagnosis but an adequate biliary imaging study should be 
considered in such patients. Several types of relationship between the autoimmune liver 
disorders in the same patient have been described: 1. sequential presentation of two 
disorders: 2. concomitant presence of two distinct disorders; autoimmune diseases are often 
associated with one another and it can be argued that an individual who has developed one 
autoimmune liver disease is predisposed to develop another one as well;  3.  existence of a 
continuum of pathological changes between two disorders, without strict boundaries and 
with “overlaps” localized in the center; 4. “overlap syndromes” are distinct entities on their 
own, with a variety of autoimmune manifestations presenting in a susceptible individual; 5. 
the presence of one primary disorder that also has one or more characteristics of another: 
this contention has been supported by a majority. The diagnosis of AIH-AIC overlap 
syndrome could be established in a patient with inflammatory colangiopathy diffuse or 
limited to intrahepatic bile duct on the presence of: 1. significant biochemical disease activity 
(moderate to severe increase of aminotransferases, hypergammaglobulinemia); 2. ANA or 
ASMA antibodies present in a titer at least ≥1:40; 3. a liver histology with interface hepatitis, 
moderate to severe lobular necrosis, moderate to severe periportal or periseptal 
inflammation. The major guidelines suggest that patients with AIH-AIC overlap syndrome 
should be treated with immunosuppressive regimen associated with ursodeoxycholic acid 
(UDCA) even if this recommendation is not evidence-based. Ursodeoxycholic acid (UDCA) 
is widely used in autoimmune cholangitis due to its beneficial effects on serum liver tests, 
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histological features, prognostic surrogate markers, and development of colonic dysplasia 
associated with accompanying ulcerative colitis, although long-term efficacy of UDCA still 
remains unproven. UDCA at higher doses (> 20 mg/kg daily) may be superior to standard 
doses and has also been used in the treatment of AIH-PSC overlap syndrome. Use of UDCA 
in combination with immunosuppressive drugs in AIH-AIC overlap syndrome, and the 
long-term course has been considered favorable in the long term. The response to 
immunosuppressive therapy appears to be better in children with AIH-AIC overlap than in 
adults. 
3.1.4 Autoimmune small duct sclerosing cholangitis (SDSC) 
A minority of patients with sclerosing cholangitis of unknown etiology with similar 
cholestatic and histologic features as those with classic PSC has normal biliary imaging, and 
they have been referred to as SDSC (Chapman, 2002). Patients with SDSC: 1. Are generally 
younger than patients with PSC and presents with more active disease, with overlap 
features; 2. may however progress to PSC and to end-stage liver disease with the consequent 
need of liver transplantation; 3. may progress to end-stage liver disease even without 
evidence of development of large-duct disease; 4. may suffer from recurrence of SDSC  in 
the allograft  in case of liver transplant; 5. do not seem to develop cholangiocarcinoma; 6. 
generally seem to have a significantly better long-term prognosis as compared with patients 
with large-duct PSC.  
3.1.5 IgG4-related sclerosing cholangitis (IgG4-SC) 
Biliary stricture, mimicking bile duct carcinoma and primary sclerosing cholangitis are 
frequently seen in IgG4-related systemic diseases. IgG4-related sclerosing cholangitis is 
almost constantly associated with autoimmune sclerosing pancreatitis (AIP).  This 
syndrome affects predominantly middle-aged and elderly patients, with male 
predominance. The patients present with symptoms referable to the involvement of one 
or more sites, usually in the form of mass lesions. also defined as type 1, most commonly 
presenting as painless obstructive jaundice with or without a pancreatic mass. Other 
common sites of involvement are the hepatobiliary tract, salivary gland, orbit, and lymph 
node, but practically any organ-site can be affected, such as retroperitoneum, aorta, 
mediastinum, soft tissue, skin, central nervous system, breast, kidney, prostate, upper 
aerodigestive tract, and lung. Some patients have low titers of autoantibodies such as 
antinuclear antibodies and rheumatoid factor. The natural history is characterized by the 
development of multiple sites of involvement with time, sometimes after many years. 
However, the disease can remain localized to one site in occasional patients. The patients 
usually have a good general condition, with no fever or constitutional symptoms. The 
disease often shows excellent response to steroid therapy with however relapse after 
steroid withdrawal. The main pathologic findings in various extranodal sites include 
lymphoplasmacytic infiltration, lymphoid follicle formation, sclerosis and obliterative 
phlebitis, accompanied by atrophy and loss of the specialized structures of the involved 
tissue (such as secretory acini in pancreas, salivary gland, or lacrimal gland). 
Immunostaining shows increased IgG4+ cells in the involved tissues (>50 per high-power 
field, with IgG4/IgG ratio >40%). The lymph nodes show an increase in IgG4+ plasma 
cells on immunostaining. The nature and pathogenesis of IgG4-related sclerosing disease 
are still elusive. Very few pediatric reports of AIP exist. 
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4. Giant cell hepatitis combined with autoimmune hemolytic anemia 
Transformation of hepatocytes into giant multinucleated cells is mostly observed in the 
neonatal period, when it is considered a nonspecific reaction of the immature liver cell to 
various forms of aggression. In older children and adults, giant cell transformation is rare 
and has been described sporadically in cases of viral, toxic, autoimmune, and genetic 
disease, as well as in diseases of unknown origin. When present, it is considered to carry a 
severe prognosis, with a risk of recurrence after liver transplantation. 
In 1981, four young children were reported associating a  giant cell hepatitis and Coombs-
positive hemolytic anemia of the immunoglobulin G-positive (IgG+) C type: three of them 
died of liver failure, but for the remaining child, immunosuppressive treatment with 
prednisone and azathioprine was beneficial. Because of the association with a positive 
Coombs test and a positive response to immunosuppressive treatment, it was postulated 
that this entity might be of autoimmune origin. Since this original description, a total of 18 
children with giant cell hepatitis and Coombs-positive hemolytic anemia have been reported   
confirming the onset of this condition in early childhood after the neonatal period, the 
severity of the liver condition that can progress to liver failure, and in many instances, the 
response to immunosuppressive treatment, but with less favorable initial control than in 
conventional autoimmune hepatitis, which occurs later in childhood. In the studies 
reported, mortality or the need for liver transplantation were 39% of reported cases and 
were due to liver cell failure and/or bacterial infection as well as relapse after liver 
transplantation. 
The diagnosis of giant cell hepatitis combined with autoimmune hemolytic anemia should 
be considered in any child between ages 1 month and 2 years presenting with autoimmune 
hemolytic anemia, acute liver disease of unknown cause, or both. Assay for serum 
aminotransferase activities should be part of the investigation in young children with 
autoimmune hemolytic anemia, both at the onset of the disease and during follow-up. 
Unexplained elevated aminotransferase activity should lead to liver biopsy in a search for 
signs of giant cell hepatitis (Figure. 7). In such cases, any reduction of the dose of steroids 
initially given to treat hemolytic anemia should be gradual, because the liver condition may 
degenerate to liver cell failure if the dose is lowered too fast. Conversely, a direct Coombs 
test should be part of the search for acute hepatitis of unknown origin in early childhood. If 
the test is positive of the IgG+ C type, liver biopsy should be performed as soon as possible; 
if giant cell hepatitis is found, immunosuppressive therapy should be rapidly started.  
Except in cases of acute refractory liver cell failure, which would require liver 
transplantation, immunosuppressive therapy with prednisone and azathioprine is the first-
line treatment. This is similar to that used in the treatment of older children with the most 
common type of autoimmune hepatitis. If appropriately administered, this treatment may 
control the liver disease. Here again, extreme caution should be exercised when reducing 
steroid doses. Thus, the high initial dose should be maintained for as long as possible until 
serum aminotransferase activity has returned to normal, because early relapse may occur. 
Hepatitis relapses are difficult to manage: in some cases they may be controlled by 
increasing the steroid dosage or adding cyclosporine to the initial regimen. Sometimes, 
however, hepatitis is refractory to drug therapy and rescue treatment with other drugs or 
biological agent such as Rituximab can be attempted. Liver transplantation must be 
considered when signs of liver failure occur early or during a relapse and are refractory to 
immunosuppressive treatment even if a relapse of the initial liver disease can be observed. 
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Fig. 10. Liver biopsy showing diffuse giant cell transformation in a child with autoimmune 
hemolytic anemia. 
The evolution of anemia may be independent of the evolution of hepatitis: anemia can be 
extremely severe and require repeated erythrocyte transfusions and may be refractory to all 
kinds of drug therapy. In such cases, Rituximab should be considered. Before Rituximab 
became available, splenectomy was used with success. Once the disease has been under 
control for 5 years of management with immunosuppressive therapy, treatment can be 
stopped in most patients without relapse of the hepatitis. 
5. Conclusions 
In conclusion, in the pediatric population two predominant forms of autoimmune diseases 
of the liver, AIH and AIC, have been clearly identified, although the distinction between the 
two diagnoses is not always easy. The diagnosis of AIH must be considered in patients who 
have symptoms and signs of acute or chronic hepatitis, particularly when an extrahepatic 
autoimmune disorder is present.  Hypergammaglobulinemia and circulating antibodies are 
of great help in supporting diagnosis of AIH. The fluctuating course of the disease can be 
responsible for alternating periods of remission and relapse. Therefore, a low-intensity 
inflammatory syndrome at onset does not preclude instituting immunosuppressive 
treatment. Rapid, complete, and sustained control of liver inflammation improves the short- 
and long-term outcome. Because it has been shown that liver fibrosis can regress in patients 
responding to treatment, an aggressive approach to confirm the diagnosis of AIH is 
justified. 
The diagnosis of AIC must be evoked in patients who have IBD and clinical and laboratory 
features of cholestasis and/or bile duct injury.  Liver biopsy and bile duct imaging are 
essential for the diagnosis and in distinguishing diffuse (PSC) from limited (SDSC) entities.  
Even if effective treatment has yet been described to control the progression of this disease, 
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patient with features overlapping with AIH may be efficaciously treated with conventional 
immunosuppressive treatment. Liver transplantation is the only definitive therapy, for 
patients with acute AIH unresponsive to rescue immunosuppressive treatment and for 
patients with end stage liver failure. Liver transplantation is also the treatment of choice for 
patient with sclerosing cholangitis and end stage liver disease. In both condition however 
the risk of relapse of the disease in the graft is not negligible. 
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